Amneal Pharmaceuticals, Inc. AMRX AvKARE — SG&A
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s avkare — sg&a.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s avkare — SG&A?
- Amneal Pharmaceuticals, Inc. (AMRX) reported avkare — SG&A of $16.68M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s avkare — SG&A changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s avkare — SG&A increased by 6.3% year-over-year, from $15.69M to $16.68M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s avkare — SG&A?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s avkare — SG&A has grown at a 2.2% compound annual growth rate (CAGR), from $57.92M to $63.18M.
- What does avkare — SG&A mean?
- Encompasses the indirect operating expenses required to support the AvKARE segment, including sales force compensation, marketing, legal, and general corporate overhead. This metric is used to assess the operational leverage and cost discipline of the segment's management team.